Analyzing the National Cholesterol Education Program Adult Treatment Panel III Report: Is New Better?
Year: 2001
Type: article
Abstract: The recently released Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III [ATP III]) summarizes an evidence-based report that expands on the clinical and scientific rationale for intensive cholesterol-lowering therapy in clinical practice. Representing 20 months of work by an expert panel comprising 27 leading clinicians and researchers, the executive summary1 is based on a lengthy (more than 200 pages), comprehensive report, available on the internet (http://www.nhlbi.nih.gov/guidelines/cholesterol/index.htm). Building on the core of the previous reports, released in 1986 (ATP I) and 1993 (ATP II), this new report constitutes a more rational, evidence-based approach to the prevention and treatment of high blood cholesterol in adults. How is this document different from its predecessors? Does it extend our ability to treat as well as prevent coronary heart disease (CHD)? How is this document applicable to the treatment of hypertension? These and other aspects of the document will be discussed in this editorial. The new summary expands on the core content of the previous two reports and proposes to update the clinical management of high blood cholesterol. In ATP I, a strategy for the primary prevention of CHD in patients without disease but with two or more risk factors and an elevated level of low-density lipoprotein cholesterol (LDL-C) was established. ATP II, expanding on the previous document, recommended that the goal for LDL-C in those with established CHD be ≤100 mg/dL. Utilizing a modified form of the Framingham risk score, the major emphasis of ATP III is on predicting the 10-year absolute risk for developing CHD in a patient with two or more risk factors (one of which may be hypertension). In all adults 20 years of age or older, a fasting lipoprotein profile (total Cholesterol, LDL-C, high-density lipoprotein [HDL-C], and triglyceride [TG]) should be obtained once every 5 years. If a nonfasting specimen is obtained, only total cholesterol and HDL-C will be usable. The major new focus is on the primary prevention of CHD, as many individuals are at high risk for CHD and will benefit from more intensive LDL-C lowering. The concept of “coronary risk equivalents” is developed. Those with peripheral arterial disease, abdominal aortic aneurysm, symptomatic carotid artery disease (transient ischemic attacks or stroke), and diabetes will be treated similarly to those with established CHD, as their risk of having a major coronary event is the same, i.e., >20% over the next 10 years. The optimal LDL-C goal of <100 mg/dL is indicated in three groups of individuals: those with CHD, those with a coronary risk equivalent, and individuals with two or more risk factors that confer a 10-year risk for CHD of >20% (based on the Framingham risk score). The five major risk factors that modify the goals for LDL-C include: age (men ≥45 years and women ≥55 years), family history of premature CHD (CHD in a male first-degree relative <55 years; CHD in a female first-degree relative <65 years), cigarette smoking (any smoking within the previous 30 days), hypertension (≥140/90 mm Hg or on antihypertensive medication), and a low HDL-C level (<40 mg/dL). As before, an HDL-C of ≥60 mg/dL removes one risk factor. As diabetes is a coronary risk equivalent, it is no longer considered a risk factor. Obesity, as in ATP II, influences glucose but is no longer considered an individual risk factor. A TG level of <150 mg/dL is considered normal. This is a departure from the previous value of 200 mg/dL given in ATP II LDL-C remains the primary target of cholesterol-lowering therapy. Although an HDL-C level of <40 mg/dL is now a categorical risk factor (raised from the previous ATP II level of 35 mg/dL), no specific goal for raising HDL-C is given. Therapeutic lifestyle change is now recognized as the most cost-effective form of therapy. ATP III recommends the previous American Heart Association step II diet as the initial diet for lowering the levels of cholesterol and saturated fat. In addition, it suggests adding plant stanols/sterols (2 g/day) and soluble fiber (10–25 g/day) to enhance LDL-C reduction. It places an increased emphasis on weight management and physical activity. ATP III recognizes the metabolic syndrome as a secondary target of therapy after LDL-C, the primary target, has been addressed. It is diagnosed when three or more of its five determinants are present: Abdominal obesity (based on waist and not umbilical circumference) TG≥150 mg/dL (atherogenic dyslipidemia) HDL-C <40 mg/dL in men and <50 mg/dL in women) (Atherogenic dyslipidemia) Insulin resistance (fasting glucose of ≥110 mg/dL) and Elevated blood pressure (≥130/85 mm Hg) Despite the fact that one half of these individuals will never develop diabetes, they are still at an increased risk of developing coronary disease. Although not a CHD risk equivalent, treatment of individuals with this prothrombotic and proinflammatory syndrome includes weight reduction and physical activity in addition to lipid level modification. Although not ready for “prime time,” but included in the report for the first time, emerging risk factors, such as an abnormal lipoprotein(a) level, an elevated homocysteine level, impaired fasting glucose, and such proinflammatory factors as high-sensitivity C-reactive protein are mentioned. No specific recommendations for treatment are provided. Preclinical atherosclerosis is mentioned, but the exact roles of coronary calcium scoring and carotid ultrasonography remain unclear and are left to the clinical judgment of the individual practitioner. Postmenopausal women are advised to use statin drugs, not hormone replacement therapy, to lower their LDL-C. Estrogen therapy is not recommended to postmenopausal women with established CHD as a means of treating abnormal lipid profiles. Lipid values should be checked within the first 24 hours of hospital admission in those with unstable coronary syndromes. If the LDL-C is ≥130 mg/dL, statin-based therapy should be initiated before discharge, to improve adherence to therapy. One of the most important changes in the new document is the inclusion of individuals with the “coronary equivalent.” This group includes patients with diabetes, symptomatic carotid artery disease, peripheral arterial disease, and evidence of an abdominal aortic aneurysm. Although they are without known CHD, they have the same 10-year risk for sustaining a nonfatal myocardial infarction (MI) or CHD death as a patient with known CHD. Accordingly, their LDL-C goal is similar: <100 mg/dL. Among patients without CHD or a coronary equivalent, the ATP III report uses a modification of the Framingham risk score to identify high-risk individuals for more intensive treatment. In both men and women with two or more risk factors, the percent probability of having a nonfatal MI or coronary death over the next 10 years is estimated. Individuals with a 10-year risk of >20% are treated as intensely as those with known CHD or a coronary equivalent (LDL-C of <100 mg/dL). The ATP III recommends that all persons without known coronary disease or a coronary equivalent but with at least two of the five major risk factors have the Framingham point score calculated. Although the LDL-C goal of >100 mg/dL in those with CHD was first recommended as “desirable” in the 1993 ATP II report, the current goal of <100 mg/dL is noted to be “optimal.” This implies that any level below 100 mg/dL is ideal. The exact level, however, for optimal benefit is being studied in ongoing clinical trials. Therefore, the word optimal appears to be too strong a recommendation at this point. Until the results of trials comparing levels of LDL-C of 70–100 mg/dL are completed, the optimal level of LDL-C to best reduce CHD events remains unclear. The LDL-C goal for those with two or more risk factors, whose 10-year risk for CHD is <20%, is 130 mg/dL. In those with one or no risk factor, the LDL-C goal is <160 mg/dL. A 10-year risk assessment is not required in these individuals, as their 10-year risk for CHD is <10%. Calculation of the Framingham risk score is one of the more important advances in the new document. Although physicians often look at the relative risk of one patient developing cardiovascular disease, this has had little direct impact on patients' motivation to modify their own risk factor profiles. Patients do want to know their own risk for heart disease, and the new document importantly allows them to know their absolute risk for developing a nonfatal MI or coronary death over the next 10 years. This is, after all, the only risk that really matters. For example, patients want to know that one in five individuals (20%) with a similar Framingham risk score will have an event over the next 10 years. With smoking cessation or control of systolic blood pressure (SBP), the reduction in risk can be estimated. This should help motivate patients to improve those risk factors that are modifiable and make changes where appropriate. Perhaps one limiting factor of the new guidelines is that they predict the risk of having a nonfatal MI and CHD death, but not total CHD events. Accordingly, events such as angina, which is the first event to occur in 50% of women and 30% of men, is not factored into the current point score analysis. Hypertension and hypercholesterolemia occur together in almost one half of patients.2 In addition, reduced HDL-C occurs in one quarter of these same individuals, highlighting the frequency of dyslipidemia in patients with hypertension. When these two risk factors occur together, they further increase the risk for coronary disease.3 For example, in the West of Scotland Trial,4 in order to prevent one coronary event, the number needed to treat in those with hypercholesterolemia was 40; this number was reduced to 24 if they were also hypertensive. Hypertension continues to be one of the five risk factors used to modify the goal for LDL-C. Defined as either a blood pressure of ≥140/90 mm Hg or being on antihypertensive medication, the presence of hypertension and one additional risk factor, such as being a man ≥45 years of age or a women ≥55 years of age, suggests that some LDL-C levels be set as if the patient had evidence of CHD. Using a modified Framingham Heart Study formula,5 the ATP III addresses the concept of global cardiovascular risk. The new guidelines stratify patients into high (>20% risk), intermediate (10%–20%), and low (<10%) risk for developing a nonfatal MI or CHD death over the next 10 years. Using separate risk tables for men and women, the new tool uses the five risk factors as noted above. It assigns an age-adjusted point score for cigarette use and total cholesterol, with more points assigned at a younger age (basing risk on the cumulative lifetime burden). Since LDL-C is the target of therapy, it is not included as a risk factor. In order to account for the 10-year delay in CHD presentation, point scores are weighted more heavily for women when they are young. SBP is appropriately used in the global risk score. It is both easy to measure and an excellent predictor for the development of CHD. SBP is a continuous variable for risk, increasing as the severity of elevation increases. Accordingly, increasing points are assigned as SBP increases from 120 mm Hg to ≥160 mm Hg. For the same level of SBP measured on treatment, a higher point score is assigned. Women receive more points than men for an elevated SBP, especially if on treatment, as women with poorly controlled blood pressure are at a higher risk than men with similar pressure. No longer included in the Framingham risk score is electrocardiographic demonstration of left ventricular hypertrophy (LVH). Accordingly, African Americans, who have more severe LVH for a given SBP, are not given special consideration in the risk score calculation. This is somewhat surprising, considering the importance of LVH as a strong independent indicator of risk. Clinical practice guidelines remain an accepted means by which medical knowledge is disseminated into primary care. Whether viewed as helpful or intrusive, they continue to have a major influence on disease management. Refinements in these documents are undertaken to make them easier to implement in clinical practice. Like all guidelines, the clinician may, at first, view the ATP III as time-consuming and difficult to implement. As we move away from cholesterol treatment and use risk factors to estimate a patient's individual risk, one hopes that use of the Framingham risk score calculation will improve individual clinical outcomes. By yearly recalculation of these risks, patients should be motivated over time to further decrease their risk. Only time will tell. Under the new guidelines, the number of Americans who may be prescribed cholesterol-lowering drugs is projected to increase from 13 million to 36 million, or nearly one in five US adults. Approximately one half of this change is a result of changing the risk factor cut-off of HDL-C from 35 mg/dL to 40 mg/dL. With an acceptable TG level of <150 mg/dL, and more individuals with an LDL-C goal of <100 mg/dL, not only will the use of statins increase, but the use of TG-lowering medications, including niacin and fibrates, will also increase. As all Americans now have an LDL goal of <160 mg/dL, the cost of achieving this “evidence-based” guideline remains unclear. Although the cumulative effect of diet can substantially reduce LDL-C (by as much as 23%), patients are more likely to ask for drug therapy, with its inherent cost, than to implement lifestyle change. It is interesting to speculate on what the recommendation might have been if statins had proved to be more effective in raising HDL levels. Would the committee have suggested that an HDL-C increase be a target of therapy, in addition to lowering LDL-C? After all, did Framingham not tell us that the total cholesterol/HDL-C ratio is very important, and that a ratio of >4–4.5 represents a major risk? Perhaps when a medication becomes available that raises the HDL-C level, the recommendation will change. Patients appear ready, and physicians should be motivated, to use this new risk calculator, either through the Palm OS® program, which can be downloaded from the Internet (at www.nhlbi.gov/guidelines/cholesterol/profmats.htm), or with score sheets kept on one's desk. It should not only have an impact on the 49% of American adults with unfavorable cholesterol levels, but also increase the focus on SBP, helping to further the commitment to better control of blood pressure in this country.
Source: Journal of Clinical Hypertension
Author: Jan N. Basile
Institution: Ralph H. Johnson VA Medical Center
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W1970854077
